Pipeline

Retatrutide: The Next GLP-1 Is a Triple Threat

·7 min read

Semaglutide targets one receptor (GLP-1). Tirzepatide targets two (GLP-1 + GIP). Retatrutide targets three: GLP-1, GIP, and glucagon. In Phase 2 trials, it produced 28.7% weight loss — more than any obesity drug in history. Eli Lilly is advancing it through Phase 3 with a regulatory submission expected in 2026. Here's what this means and when it could be available.

Why Three Receptors Matter

Each receptor in retatrutide's triple agonist profile does something different:

GLP-1 receptor: Suppresses appetite, slows gastric emptying, improves insulin secretion. This is the same target as semaglutide and the GLP-1 component of tirzepatide. It's the foundation of every obesity drug in this class.

GIP receptor: Gastric inhibitory polypeptide receptor. Works synergistically with GLP-1 to enhance insulin signaling, improve fat metabolism, and amplify the appetite-suppressing effect. This is tirzepatide's second target, and it's a significant part of why tirzepatide outperforms semaglutide.

Glucagon receptor: This is retatrutide's unique addition. Glucagon is traditionally thought of as the "opposite of insulin" — it raises blood sugar and promotes energy expenditure. By activating the glucagon receptor, retatrutide appears to increase resting energy expenditure (your body burns more calories at rest) and promote hepatic fat oxidation (your liver burns more stored fat). In simple terms: you eat less AND burn more. The glucagon agonism may also be why retatrutide shows such dramatic effects on liver fat.

The Phase 2 Numbers

In the Phase 2 study published in the New England Journal of Medicine, participants on the highest dose of retatrutide (12mg weekly) lost an average of 24.2% of body weight at 48 weeks. The weight loss curve had not yet plateaued, and investigators projected 28.7% at full effect — weight loss territory that had previously only been achievable through bariatric surgery.

For comparison: semaglutide 2.4mg produces roughly 15–17% weight loss in clinical trials. Tirzepatide's maximum dose achieves approximately 20–22%. Retatrutide's 28.7% represents a meaningful step-change — roughly 50% more weight loss than the current best-in-class.

The Knee Pain Data

One of the most relevant findings for men came from the TRIUMPH-4 trial, which studied retatrutide in patients with obesity and knee osteoarthritis. The results showed a 75.8% reduction in WOMAC pain scores — meaning patients reported dramatically less knee pain alongside the weight loss.

For men who carry excess weight and have joint pain that limits activity, this is a big deal. Knee osteoarthritis disproportionately affects men with obesity, and it creates a vicious cycle: weight causes joint pain, joint pain prevents exercise, lack of exercise prevents weight loss. Retatrutide appears to break that cycle from both directions — reducing load through weight loss and reducing pain through anti-inflammatory mechanisms.

Phase 3 and Timeline

Eli Lilly's Phase 3 program for retatrutide includes multiple trials across different indications:

TRIUMPH-4 (December 2025 topline data): obesity with knee osteoarthritis. 28.7% weight loss confirmed.

TRANSCEND-T2D-1 (March 2026 data): retatrutide in type 2 diabetes. Results showed 2% A1C reduction and 17% weight loss — establishing the diabetes indication alongside obesity.

Regulatory submission is expected in 2026. If accepted for priority review, the earliest FDA approval would be late 2027. Realistic availability for patients: sometime in 2028, assuming a smooth regulatory path and manufacturing scale-up.

The Muscle Question

With nearly 30% total body weight loss, the lean mass question becomes critical. No drug that produces this degree of caloric deficit will spare muscle entirely. The composition data from Phase 2 hasn't been fully reported, but at this magnitude of weight loss, aggressive protein and resistance training protocols become non-optional.

The glucagon receptor agonism could theoretically favor fat loss over lean mass loss (glucagon promotes fat oxidation), but this hasn't been confirmed in body composition studies. Men considering retatrutide when it becomes available should plan their training and nutrition protocol in advance — the deficit will be extreme.

What This Means Right Now

You can't get retatrutide yet. It's not approved, not available through compounding, and not available off-label. But its existence shapes the landscape in several ways:

It puts competitive pressure on Novo Nordisk's semaglutide franchise. CagriSema (semaglutide + cagrilintide) is Novo's answer, with an FDA response expected in 2026 — but even CagriSema achieves approximately 22–24% weight loss, short of retatrutide's numbers.

It validates the multi-agonist approach. The future of obesity pharmacotherapy is clearly moving toward drugs that hit multiple metabolic pathways simultaneously. Retatrutide at three receptors is likely not the ceiling — quad-agonists and beyond are in preclinical development.

For men currently deciding between semaglutide and tirzepatide, the practical advice is: don't wait for retatrutide. Start with what's available now. You can always switch when more effective options reach the market. Two years of weight loss progress on current drugs is worth more than two years of waiting for a marginally better one.

Compare Men's GLP-1 Providers

Start with what's available today — compare semaglutide and tirzepatide providers.

View Providers →

Sources